BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Status:
Completed

Trial end date:
2016-03-17

Target enrollment:

Participant gender:

The purpose of this phase II study is to find out if an investigational drug called LGX818 can stop the melanoma from growing.

Phase 2

Memorial Sloan Kettering Cancer Center

Array BioPharma